Purple Biotech Ltd. Updates Company Presentation
Ticker: PPBT · Form: 6-K · Filed: Dec 6, 2024 · CIK: 1614744
Sentiment: neutral
Topics: company-update, investor-relations
TL;DR
Purple Biotech dropped a new investor deck on their site 12/6.
AI Summary
On December 6, 2024, Purple Biotech Ltd. announced it has made available an updated Company Presentation on its website. This presentation is attached as Exhibit 99.1 to the filing.
Why It Matters
Investors and interested parties can access the latest information and strategic overview of Purple Biotech Ltd. directly from the company's updated presentation.
Risk Assessment
Risk Level: low — This filing is an informational update regarding a company presentation and does not contain significant financial or operational changes.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer of the report
- December 6, 2024 (date) — Date of the announcement and filing
- Exhibit 99.1 (document) — Attached company presentation
FAQ
What is the purpose of this 6-K filing?
The purpose of this 6-K filing is to report that Purple Biotech Ltd. has made an updated Company Presentation available on its website as of December 6, 2024.
Where can the updated Company Presentation be found?
The updated Company Presentation is attached to the filing as Exhibit 99.1 and can be viewed on the company's website.
What is the filing date of this report?
The filing date of this report is December 6, 2024.
What is the Central Index Key (CIK) for Purple Biotech Ltd.?
The Central Index Key (CIK) for Purple Biotech Ltd. is 0001614744.
What was Purple Biotech Ltd.'s former name?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-12-06 07:30:26
Filing Documents
- ea0223901-6k_purplebio.htm (6-K) — 14KB
- ea022390101ex99-1_purplebio.htm (EX-99.1) — 80KB
- ex99-1_001.jpg (GRAPHIC) — 118KB
- ex99-1_002.jpg (GRAPHIC) — 1094KB
- ex99-1_003.jpg (GRAPHIC) — 89KB
- ex99-1_004.jpg (GRAPHIC) — 99KB
- ex99-1_005.jpg (GRAPHIC) — 120KB
- ex99-1_006.jpg (GRAPHIC) — 123KB
- ex99-1_007.jpg (GRAPHIC) — 140KB
- ex99-1_008.jpg (GRAPHIC) — 145KB
- ex99-1_009.jpg (GRAPHIC) — 126KB
- ex99-1_010.jpg (GRAPHIC) — 139KB
- ex99-1_011.jpg (GRAPHIC) — 124KB
- ex99-1_012.jpg (GRAPHIC) — 96KB
- ex99-1_013.jpg (GRAPHIC) — 87KB
- ex99-1_014.jpg (GRAPHIC) — 96KB
- ex99-1_015.jpg (GRAPHIC) — 93KB
- ex99-1_016.jpg (GRAPHIC) — 105KB
- ex99-1_017.jpg (GRAPHIC) — 106KB
- ex99-1_018.jpg (GRAPHIC) — 124KB
- ex99-1_019.jpg (GRAPHIC) — 118KB
- ex99-1_020.jpg (GRAPHIC) — 107KB
- ex99-1_021.jpg (GRAPHIC) — 106KB
- ex99-1_022.jpg (GRAPHIC) — 127KB
- ex99-1_023.jpg (GRAPHIC) — 92KB
- ex99-1_024.jpg (GRAPHIC) — 84KB
- ex99-1_025.jpg (GRAPHIC) — 117KB
- ex99-1_026.jpg (GRAPHIC) — 109KB
- ex99-1_027.jpg (GRAPHIC) — 142KB
- ex99-1_028.jpg (GRAPHIC) — 132KB
- ex99-1_029.jpg (GRAPHIC) — 113KB
- ex99-1_030.jpg (GRAPHIC) — 106KB
- ex99-1_031.jpg (GRAPHIC) — 117KB
- ex99-1_032.jpg (GRAPHIC) — 90KB
- ex99-1_033.jpg (GRAPHIC) — 81KB
- ex99-1_034.jpg (GRAPHIC) — 133KB
- ex99-1_035.jpg (GRAPHIC) — 91KB
- ex99-1_036.jpg (GRAPHIC) — 92KB
- ex99-1_037.jpg (GRAPHIC) — 117KB
- ex99-1_038.jpg (GRAPHIC) — 87KB
- ex99-1_039.jpg (GRAPHIC) — 95KB
- ex99-1_040.jpg (GRAPHIC) — 75KB
- ex99-1_041.jpg (GRAPHIC) — 110KB
- ex99-1_042.jpg (GRAPHIC) — 110KB
- ex99-1_043.jpg (GRAPHIC) — 110KB
- ex99-1_044.jpg (GRAPHIC) — 129KB
- ex99-1_045.jpg (GRAPHIC) — 115KB
- ex99-1_046.jpg (GRAPHIC) — 120KB
- ex99-1_047.jpg (GRAPHIC) — 37KB
- ex99-1_048.jpg (GRAPHIC) — 81KB
- ex99-1_049.jpg (GRAPHIC) — 80KB
- ex99-1_050.jpg (GRAPHIC) — 119KB
- ex99-1_051.jpg (GRAPHIC) — 109KB
- ex99-1_052.jpg (GRAPHIC) — 75KB
- ex99-1_053.jpg (GRAPHIC) — 153KB
- ex99-1_054.jpg (GRAPHIC) — 93KB
- ex99-1_055.jpg (GRAPHIC) — 89KB
- ex99-1_056.jpg (GRAPHIC) — 134KB
- ex99-1_057.jpg (GRAPHIC) — 523KB
- 0001213900-24-106203.txt ( ) — 10405KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. December 6, 2024 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2